Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1973 3
1974 1
1975 4
1976 9
1977 2
1978 5
1979 2
1980 3
1981 5
1982 5
1983 7
1984 7
1985 15
1986 8
1987 5
1988 3
1989 6
1990 15
1991 8
1992 8
1993 5
1994 11
1995 8
1996 13
1997 19
1998 16
1999 17
2000 17
2001 17
2002 19
2003 18
2004 13
2005 17
2006 13
2007 14
2008 19
2009 18
2010 20
2011 17
2012 22
2013 29
2014 31
2015 32
2016 23
2017 32
2018 27
2019 23
2020 17
2021 22
2022 13
2023 15
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

659 results

Results by year

Filters applied: . Clear all
Page 1
Alpha-1 antitrypsin deficiency.
Dasí F. Dasí F. Med Clin (Barc). 2024 Apr 12;162(7):336-342. doi: 10.1016/j.medcli.2023.10.014. Epub 2023 Nov 22. Med Clin (Barc). 2024. PMID: 37993348 Free article. Review. English, Spanish.
AATD patients face challenges such as under diagnosis, clinical variability, and limited treatment options for liver disease. Early detection and biomarkers for predicting outcomes are needed to improve patient outcome. Currently, the only approved pharmacological therapy …
AATD patients face challenges such as under diagnosis, clinical variability, and limited treatment options for liver disease. Early detectio …
Alpha-1 antitrypsin deficiency: outstanding questions and future directions.
Torres-Durán M, Lopez-Campos JL, Barrecheguren M, Miravitlles M, Martinez-Delgado B, Castillo S, Escribano A, Baloira A, Navarro-Garcia MM, Pellicer D, Bañuls L, Magallón M, Casas F, Dasí F. Torres-Durán M, et al. Orphanet J Rare Dis. 2018 Jul 11;13(1):114. doi: 10.1186/s13023-018-0856-9. Orphanet J Rare Dis. 2018. PMID: 29996870 Free PMC article. Review.
New strategies for early detection and biomarkers for patient outcome prediction are needed to reduce morbidity and mortality in these patients; 3) Augmentation therapy is the only specific approved therapy that has shown clinical efficacy in delaying the progression of em …
New strategies for early detection and biomarkers for patient outcome prediction are needed to reduce morbidity and mortality in thes …
α1-Antitrypsin deficiency and chronic respiratory disorders.
Cazzola M, Stolz D, Rogliani P, Matera MG. Cazzola M, et al. Eur Respir Rev. 2020 Feb 12;29(155):190073. doi: 10.1183/16000617.0073-2019. Print 2020 Mar 31. Eur Respir Rev. 2020. PMID: 32051168 Free PMC article. Review.
Alpha-1 antitrypsin deficiency.
Kelly E, Greene CM, Carroll TP, McElvaney NG, O'Neill SJ. Kelly E, et al. Respir Med. 2010 Jun;104(6):763-72. doi: 10.1016/j.rmed.2010.01.016. Epub 2010 Mar 20. Respir Med. 2010. PMID: 20303723 Free article. Review.
Alpha-1 Antitrypsin Deficiency and Pregnancy.
Gaeckle NT, Stephenson L, Reilkoff RA. Gaeckle NT, et al. COPD. 2020 Jun;17(3):326-332. doi: 10.1080/15412555.2020.1754778. Epub 2020 Apr 20. COPD. 2020. PMID: 32308050
While there is a significant heterogeneity in disease presentation in relation to the severity of symptoms and prognosis, it is not uncommon for young individuals, including pregnant women to already have moderate to advanced lung disease at the time of diagnosis. ...Ultim …
While there is a significant heterogeneity in disease presentation in relation to the severity of symptoms and prognosis, it is not u …
Alpha1-antitrypsin deficiency: An updated review.
Mornex JF, Traclet J, Guillaud O, Dechomet M, Lombard C, Ruiz M, Revel D, Reix P, Cottin V. Mornex JF, et al. Presse Med. 2023 Sep;52(3):104170. doi: 10.1016/j.lpm.2023.104170. Epub 2023 Jul 29. Presse Med. 2023. PMID: 37517655 Review.
Based on a randomized clinical trial, augmentation therapy is indicated in non-smoking adults less than 70 years of age with emphysema at chest CT, confirmed homozygous AATD, and FEV1 between 35% and 70% of predicted. In contrast Z heterozygosis (MZ or SZ) brings a risk of …
Based on a randomized clinical trial, augmentation therapy is indicated in non-smoking adults less than 70 years of age with emphysema at ch …
Relationship between alpha-1 antitrypsin deficiency and obstructive sleep apnea.
Megenhardt L, Ransdell S, Clark-LoCascio J, Pleasants RA, Brantly M, Strange C. Megenhardt L, et al. Sleep Breath. 2021 Dec;25(4):2091-2097. doi: 10.1007/s11325-021-02386-0. Epub 2021 Apr 30. Sleep Breath. 2021. PMID: 33931809
The 11.2% prevalence of diagnosed OSA in the AATD population is much lower than symptom scores would predict. Further studies are needed to validate the possibility that elastin loss is involved in OSA pathogenesis....
The 11.2% prevalence of diagnosed OSA in the AATD population is much lower than symptom scores would predict. Further studies are nee …
Gene therapy for alpha-1 antitrypsin deficiency: an update.
Pires Ferreira D, Gruntman AM, Flotte TR. Pires Ferreira D, et al. Expert Opin Biol Ther. 2023 Mar;23(3):283-291. doi: 10.1080/14712598.2023.2183771. Epub 2023 Mar 2. Expert Opin Biol Ther. 2023. PMID: 36825473 Review.
Although gene therapy products are already a reality for the treatment of some pathologies, such as inherited retinal dystrophy and spinal muscular atrophy, AATD-related pulmonary and, especially, liver diseases still lack effective therapeutic options. AREAS COVERED: Here, we re …
Although gene therapy products are already a reality for the treatment of some pathologies, such as inherited retinal dystrophy and spinal m …
659 results